drugset
drugset / Trial / NCT03840512

An Open Label Study of Multiple Doses of Cannabidiol in the Prevention of Acute Graft-Versus-Host Disease (GVHD)

NCT03840512 ↗

Phase 2 Unknown 36 enrolled Kalytera Therapeutics Israel, Ltd.
Non-randomizedSequentialOpen-labelPrevention

Summary

A prospective, open-label, phase 2a study, to evaluate the pharmacokinetic (PK) profile, safety, and efficacy of multiple doses of Cannabidiol (CBD) in participants Graft-Versus-Host Disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT)

Timeline

Start
2018-06-12
Primary completion
2022-11-15
Completion
2022-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Cannabidiol Other / unclassified 75 mg Oral
Subject Cannabidiol Other / unclassified 150 mg Oral
Subject Cannabidiol Other / unclassified 300 mg Oral

Indications

acute graft versus host disease